TITLE

CRUCELL/AERAS START TURBERCULOSIS VACCINE CLINICAL TRIAL

PUB. DATE
December 2006
SOURCE
Worldwide Biotech;Dec2006, Vol. 18 Issue 12, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on phase I clinical trial of the AdVac-based tuberculosis vaccine started by Crucell N.V. The vaccine is being developed in partnership with the AERAS Global TB Vaccine Foundation. The trial will test the vaccine in a dose-escalation trial involving healthy volunteers. AdVac technology is a vaccine technology manufactured by Crucell and is said to play a role in the prevention of emerging and re-emerging infectious diseases, and in biodefense.
ACCESSION #
23154770

 

Related Articles

  • CLINIC ROUNDUP.  // BioWorld Today;12/26/2007, Vol. 18 Issue 248, p2 

    This section offers news briefs related to the biotechnology industry. The first patient in the first phase of the clinical trial of CB3304 was enrolled by Cougar Biotechnology Inc. A Phase 1 BCG-Ad35 prime boost trial of a tuberculosis vaccine will be conducted by Crucell NV and Aeras Global TB...

  • CLINIC ROUNDUP.  // BioWorld Today;4/29/2009, Vol. 20 Issue 81, p3 

    This section offers news briefs concerning the biotechnology industry. A Phase I trial of AERAS-402/Crucell Ad35 tuberculosis vaccine has been started by Crucell NV and the Aeras Global TB Vaccine Foundation. Inimex Pharmaceuticals Inc. has commenced its Phase I study of IMX942, an innate...

  • Tuberculosis Vaccines: Current Progress. Orme, Ian M. // Drugs;2005, Vol. 65 Issue 17, p2437 

    Tuberculosis continues to be a major cause of disease and death throughout the developing world. Chemotherapy is the current method of control but with the continuing emergence of drug resistance, coupled with the reticence of major drug companies to invest in drug discovery, the identification...

  • AERAS/CRUCELL TO DEVELOP TB VACCINE.  // Worldwide Biotech;May2004, Vol. 16 Issue 5, p4 

    Focuses on the collaboration between Crucell NV and Aeras Global TB Vaccine Foundation of Bethesda, Maryland, on the pre-clinical and clinical development of candidate tuberculosis (TB) vaccines. Information on the Crucell-Aeras TB vaccine program; Details on Crucell's TV and malaria vaccine...

  • Crucell receives $5 million for TB vaccine development.  // European Pharmaceutical Executive;May2007, p9 

    The article reports on the amount to be received by the Netherlands-based Crucell NV (CN) for developing a tuberculosis (TB) vaccine. CN will obtain up to $5 million from U.S.-based Aeras Global TB Vaccine Foundation to support the advanced development of the Advac-based TB vaccine. This...

  • Lack of efficacy of MVA85A TB vaccine candidate: potential outcomes. KENNETH, JOHN // Current Science (00113891);6/25/2013, Vol. 104 Issue 12, p1594 

    A letter to the editor is presented regarding a clinical trial in Cape Town, South Africa which revealed the lack of efficacy of a tuberculosis (TB) vaccine.

  • CRUCELL REPORTS 2004 THREE-FOLD INCREASE OVER 2003 REVENUE.  // Biotech Financial Reports;Mar2005, p4 

    The articles deals with the 2004 financial performance of the Dutch biotechnology company Crucell NV based in Leiden, Netherlands. Revenue for the year ended December 31, 2004 was � 22.6 million (US$ 30.9 million), representing a three-fold increase over the � 7.4 million (US$ 10.1...

  • Clinical Trials for New TB Vaccine to Start in March. Kingman, Sharon // BioWorld International;1/26/2011, Vol. 16 Issue 6, p1 

    This article reports that clinical trials of a candidate vaccine that will prevent adults from developing tuberculosis (TB) and will stop reactivation of Mycobacterium tuberculosis are due to begin in Cape Town, South Africa in March 2011. The Phase I trials will begin in people infected with...

  • J&J/Crucell: influenza deal signals shifts in the wider flu market.  // PharmaWatch: Monthly Review;Nov2009, Vol. 8 Issue 11, p33 

    The article focuses on the joint effort of Johnson & Johnson and Crucell NV to develop and commercialize the universal influenza antibodies of the latter for treating and preventing influenza. It notes that the deal strengthens the presence of Johnson & Johnson in treating infectious diseases....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics